Pharmaceuticals company Fermenta Biotech announced Q1FY26 results Q1FY26 Consolidated Revenue Rs 145 crore, up 79% YoY. Consolidated EBITDA for Q1FY26 Rs 37 crore, up 922% YoY. PAT: Rs 21.6 crore vs Rs 5.9 crore loss during Q1FY25. EPS: Rs 7.49 for Q1FY26. Prashant Nagre, Managing Director, said: “Continuing our financial and operational turnaround of FY25, we delivered exceptional performance this quarter with strong YoY growth in revenue and EBITDA, driven by robust volume and price expansion across our human and animal nutrition segments. Fermenta’s strategic initiatives, including partnerships with NIFTEM-T and GAIN, strengthen our market position for sustained future growth." Result PDF
Pharmaceuticals company Fermenta Biotech announced Q3FY25 results Revenue: Rs 156.5 crore (up 58 % YoY, up 65 % QoQ). EBITDA: Rs 55.5 crore (up 101 % YoY, up 156 % QoQ). Profit after tax: Rs 37.9 crore (up 279 % YoY, up 241 % QoQ). EPS: Rs 12.71 (up 273 % YoY, up 222 % QoQ). Prashant Nagre, Managing Director, said: “The significant YoY and QoQ increase in revenue and EBITDA was on the back of volume and price growth in both Human and Animal Nutrition. Increased market demand in the Human Nutrition segment in key markets such as North America and Europe; approvals with key global accounts in animal nutrition also led to increased volumes in this segment.” Result PDF
Conference Call with Fermenta Biotech Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.
Conference Call with Fermenta Biotech (DIL) Management and Analysts on Q2FY22 Performance and Outlook. Listen to the full earnings transcript.